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ABSTRACT
Objective: This study was designed to evaluate the protective effect of Canna indica L., (CI) extract against caffeine-nicotine administration-induced 
Type 2 diabetes exaggeration in rats.
Methods: A study was conducted for 3 weeks in four rat groups (n=6); viz., Type 2 diabetic control group, a caffeine-nicotine diabetic control group 
(20 mg/kg, 0.4 mg/kg, i.p. twice daily), and CI extract and caffeine-nicotine treatment group and standard drug-treated caffeine-nicotine diabetic 
group (glibenclamide, 5 mg/kg, once daily). Type 2 diabetes was induced by 2 weeks high fatty diet and a single dose streptozotocin (50 mg/kg, i.p.) 
on 1th day of the study in all groups. Blood and urine samples were collected every week for serum biochemical analysis.
Results: Results of extract treatment and standard drug treatment were compared with untreated caffeine-nicotine coadministration group. 
Difference in each relevant serum parameter was analyzed through ANOVA and Dunett’s t-test. Extract-treated caffeine-nicotine-diabetic group 
showed about 150-200 mg/dL (p<0.001) reduction in the serum glucose than untreated caffeine-nicotine-diabetic control (DCN) group. Extract 
treatment reduces serum glucose by 10-15 mg/dL than glibenclamide treatment with higher significance (p<0.001). Extract treatment showed better 
results than standard drug in liver and kidney function test and exhibited its better potential in controlling diabetic complications. Extract treatment 
increased high-density lipid-cholesterol and reduced triglycerides, low-density lipid-cholesterol (LDL-C), very LDL-C, and total cholesterol (TC) much 
better and with higher significance than standard drug. Extract treatment reduced TC by at least 60-80 mg/dL (p<0.01) in comparison to DCN group. 
Extract treatment reduced 10-15 mg/dL of more TC than that of standard drug.
Conclusion: Caffeine-nicotine coadministration-induced exaggeration of Type 2 diabetes was better treated by CI extract than that of standard drug 
glibenclamide.
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INTRODUCTION
Diabetes is called a lifestyle disease. Due to urbanization in late 
20th century and early 21st century large population of developing 
countries is shifting to urban area [1,2]. The people who were living 
very peaceful life in villages are now facing very hectic lifestyle in urban 
areas. This change has loaded a huge mental stress on urban population 
and their present generation [3]. With lifestyle food habits have 
changed a lot. Simple and pure food now has become much complex 
and adulterated one. Uncomfortable time schedules, night-shifts, poor 
hygiene, and lack of physical exercise are observed as reasons for 
increased incidences of early diabetes [4]. Due to increase in the stress; 
population has got attracted toward addictions also [5]. Addiction is 
generally observed for tobacco products, alcohol, other drinks, and 
drugs. There is a link between diabetes and addictions; particularly, 
nicotine and alcohol. Tobacco chewing and smoking both are found to 
increase insulin resistance while alcohol is found to harm pancreatic 
islets [6]. This link was the major focus of this research.
In our previous study, we demonstrated exaggeration of streptozotocin 
(STZ)-induced Type 2 diabetes in rats due to caffeine-nicotine 
coadministration [7]. When we compared diabetic control group 
with coadministration group we observed increase in insulin 
resistance, hyperglycemia, and hyperlipidemia. We also demonstrated 
change in histopathology of vital organs such as pancreas, kidney, 
and liver of diabetic animals and concluded, “there was mild to 
moderate exaggeration of organ damage in diabetes due to chronic 
coadministration of caffeine-nicotine” [7].
Along with the insulin and hypoglycemic drug therapy herbal drugs are 
being used either as alternative or as adjuvant to the therapy. Herbal 
drug is known to have several benefits which help significantly in the 
management of diabetes. They are popular due to ease of availability, lack 
of potential side effects, and other benefits such as antioxidant activity 
and nutritional benefits. Use of herbal drugs in diabetes is being practiced 
all over the world, particularly in developing and poor countries [8].
Rahmatullah et al., in 2009, conducted a survey in Thakurgaon district 
of Bangladesh where he observed that different tribes residing around 
use large amount of medicinal plants to cure their diseases. Water 
extract of Canna indica L. (CI) whole herb was being given orally to treat 
diabetes [9]. Purintrapiban et al. described differential activation of 
glucose transporters (GLUT) in cultured muscle cells by polyphenolic 
compounds from CI and proposed the interference of these compounds 
with different GLUT [10]. On this basis, we selected water extract of 
this plant to treat diabetes and its exaggeration caused by addiction of 
caffeine and nicotine.
CI is known as “Indian shot” and generally found in gardens as 
flowering plant. It has been cultivated since historical times at different 
geographical areas of the world. It is native to South-Central America 
(Andes), West Indies, Mexico, Europe, Africa and Asia. Flowers of CI 
plant are the rich source of anthocyanin color pigments. These eatable 
pigments can be used as antioxidant nutraceutical in food industry [11].
There are numerus ethnopharmacological uses of different parts of CI 
herb recommended by traditional medical practitioners in Thailand, 
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Bangladesh, Philippine, and India. Rhizome is considered diuretic, 
demulcent, antipyretic, and diaphoretic. Decoction of rhizome is useful 
in treating dyspepsia, dropsy, hepatitis, and jaundice. Roots are said to 
be acrid and stimulant [12]. These medicinal activities are traditional 
beliefs of tribes and they lack proper evidence in the form of clinical 
documentation.
“How to minimize the additional exaggeration of complication caused 
by nicotine-caffeine in Type 2 diabetes?” was the main focus of this 
study [7,13]. We treated caffeine-nicotine addicted diabetic animals 
with standard drug glibenclamide and CI extract in different groups. 
Results of the extract treatment were statically tested against caffeine-
nicotine-diabetic control (DCN) group while compared with standard 
group in the evaluation.
METHODS
Materials
Analytical grade chemicals were used throughout the work. Caffeine 
and nicotine (Tokyo Chemical Industry, Japan), STZ (Sisco Research 
Lab, Mumbai, India), biochemical estimation kit (Biolab Diagnostics 
(Pvt.), Ltd., Mumbai, India), and animal feed (Nutrivet Life Sciences, 
Pune, India) were used.
Methods
Extract preparation
Flower bearing plants 2-3 m in height were collected from botanical 
garden located in Pune. The CI plant sample selected for the work 
was submitted and subsequently authenticated by the regional 
government institute “Botanical Survey of India, Koregaon park, Pune” 
with voucher code (SK01). Rhizome and roots were dried in a lab for 
15 days and powdered using mixer blender. The resulting mass was 
macerated in ethanol:water (1:1) solvent for 24 hrs [14]. Resultant 
liquid was concentrated to semi-solid mass by evaporating solvent 
by rotary evaporator (Evator, South Africa). Concentrate was filled in 
sterile amber glass bottle. One kilogram of powdered drug gave 9.33 g 
of extract (approximately 1% yield). Extract was stored at cool place 
and dry place till its administration in rats. Preliminary phytochemical, 
qualitative and quantitative analysis of this CI extract was performed as 
per our previous study [15].
Animals used
Sprague Dawley male rats were procured from Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA) 
approved supplier, and they were kept in quarantine for 7 days to 
acclimatize with animal house condition. After acclimatization, animals 
were shifted to 12 hrs auto-controlled light-dark cycle in a separate room. 
Except during the experiment, animals were kept on adequate supply of 
standard diet and purified water. Animals of age 8-10 weeks and body 
weight 150-200 g were selected randomly for the study.
Antidiabetic activity
During the experiment, animals were kept on the standard diet and 
sufficient water. Animals were divided into four groups containing ten 
animals in each group. All animals were fed with high fat diet (HFD) for 
2 weeks and single dose STZ was injected on 1st day to induce Type 2 
diabetes [16]. Groups II, III and IV were administered with normal 
doses of (i.p.) caffeine and nicotine twice daily to produce addiction 
for 3-week period [17]. On 7th day after STZ administration, six stable 
animals were selected for further study while four animals were 
removed from each group. Extract and glibenclamide were suspended 
in 5% acacia solution and administered orally in overnight fasted rats 
by gastric intubation. Group III was treated orally with 200 mg/kg of 
CI extract and Group IV was treated with standard drug glibenclamide 
(5 mg/kg, p.o.) once daily for 3 weeks. Group I was plane diabetic 
control (D), Group II was DCN, Group III was extract-treated caffeine-
nicotine-diabetic group (EDCN) while Group IV was standard drug 
glibenclamide-treated caffeine-nicotine-diabetic group (GDCN). Blood 
samples were drawn from retro orbital sinus weekly till the end of 
study (i.e., 3 weeks). Fasting blood glucose estimation and body weight 
measurements were conducted on 1, 7, 14, and 21st day of the study. On 
21st day animals were anesthetized and sacrificed. Room temperature 
of 20±5°C and relative humidity of 60±10% was maintained throughout 
the study.
This study was conducted in compliance with guidelines published by the 
CPCSEA. Approval of the Institutional Animal Ethics Committee (IAEC) 
was obtained before the initiation of the study (IAEC-16-004). Study 
was completed within 6 months form the date of approval.
Clinical biochemistry
Each animal was anesthetized adequately using diethyl ether and blood 
was withdrawn from orbital plexus by capillary method. Blood was 
collected in a labeled vial containing sodium heparin anticoagulant. 
These vials were rotated at 3000 rpm for 15 minutes in a centrifuge 
(Remi, Mumbai, India) to separate the components of blood. Serum was 
separated and analyzed using EM density 180 clinical chemistry analyzer 
(Erba diagnostics, Germany). Ready-to-use reagents were procured 
to estimate serum levels of glucose, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), creatinine (CRE), urea (BU), 
triglycerides (TG), high-density lipid-cholesterol (HDL-C), low-density 
lipid-cholesterol (LDL-C), and total cholesterol (TC).
Statistical analysis
Each group was containing at least six animals to statistically generalize 
the outcome. Results were presented as mean±standard error of mean. 
Treatment groups were analyzed against different control groups using 
one-way ANOVA and Dunnett’s t post-test. Significance was determined 
in terms of p value; and p<0.05 was considered significant. Different 
levels of significance utilized in the study were a: (p<0.05), b: (p<0.01) 
and c: (p<0.001) for test and x: (p<0.05) between control groups.
RESULTS
Body weight analysis
Induction of diabetes always leads to acute polyuria in the animal. This 
polyuria further creates dehydration and weakness. In D group, there 
was progressive weight loss parallel to diabetes. In DCN group, there 
was little more weight loss than D group. In EDCN and GDCN groups, 
there was negligible weight loss compared to the control groups. There 
was no full weight recovery in any group after diabetes induction even 
after treatment (Fig. 1).
Clinical biochemistry
Serum glucose levels
Fasting glucose level was estimated in early morning blood of target 
animals. Diabetic control group rats (D) showed expected rise in serum 
glucose level and exhibited successful induction of Type 2 diabetes. 
Caffeine-nicotine diabetic control showed even more increase in glucose 
level about 50-60 mg/dL (p<0.05). Extract treatment group showed 
progressive reduction in the blood glucose about 150-200 mg/dL (p<0.001) 
less than diabetic caffeine-nicotine group. Glibenclamide-treated GDCN 
group showed significant (p<0.05) rise in blood glucose as like extract 
treatment group. Extract treatment showed better control on average 
blood glucose than standard drug by 20-30 mg/dL (Fig. 2).
Liver function test
Serum AST and ALT are metabolic enzymes secreted by liver which 
were estimated to demonstrate liver function. Diabetic control 
animals showed progressive increase in AST, ALT levels; approximately 
2-3 times greater than that of normal. Group DCN showed much intense 
rise in AST ALT than plane diabetic group. Extract treatment (in EDCN) 
reduced concentration of these enzymes in blood better than standard 
drug treatment (in GDCN) by 30-40U/L (p<0.01) and 150-200U/L, 
respectively, (p<0.001). Here, also extract showed better control on 
these levels than that of standard drug (Table 1).
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Kidney function test
Serum urea and CRE levels are indicators of kidney damage in 
diabetes. DCN group showed more elevation of these levels than 
plane diabetic control possibly due to additional damage caused 
by caffeine-nicotine administration. Extract-treated EDCN group 
showed less kidney damage than that of standard drug-treated GDCN 
group. About 30-40 mg/dL of less urea was observed in treatment 
groups than that of diabetic control groups (p<0.001) while 
0.3-0.4 mg/dL of less CRE was observed in treatment groups than 
that of control groups (p<0.01). Here, also extract treatment show 
lesser concentration of urea and CRE in blood compared to standard 
drug (Table 2).
Lipid profile
Diabetes being metabolic disorder increases TG in blood called 
diabetes-induced triglyceridemia. There was marked increase in blood 
TG level in diabetic control animals.
Triglyceridemia is more in animals with caffeine-nicotine treatment 
compared to plane diabetic control by about 20 mg/dL (p<0.05). 
Triglyceridemia was much better controlled by the CI herbal extract 
treatment (40-50 mg/dL) compared to glibenclamide treatment 
(30-40 mg/dL). There was difference of 8-12 mg/dL (0.05) of TG 
between EDCN and GDCN group blood (Table 3).
HDL-C is identified as beneficial cholesterol and it is a marker of healthy 
normal blood. Diabetes in step-wise manner reduce this cholesterol 
as evident in both the control groups. Plane diabetic control showed 
less reduction in HDL-C as compared to caffeine-nicotine administered 
controlled. Extract treatment promotes approximately 4-6 mg/dL rise 
in HDL-C in EDCN group than GCDN group rats. Extract treatment 
showed clear benefit by promoting good fats, i.e., HDL-C (Table 3).
The LDL-C is generally linked with the cardiovascular complication 
of the Type 2 diabetes. In plane control group, there was continuous 
rise in LDL-C during the study period. This rise was still much less 
than exaggerated rise observed in DCN control group by 15-20 mg/dL 
(p<0.05). Extract treatment in EDCN group showed that it greatly reduces 
this increasing harmful fat, LDL-C though caffeine-nicotine exaggerate 
it. Extract treatment reduces average 10-12 mg/dL (p<0.01) of LDL-C 
in EDCN rats than that of standard drug-treated GDCN rats (Table 3).
There was additional rise in very LDL-C (VLDL-C) in case of 
caffeine-nicotine DCN control than that of plane diabetic control D 
by 12-15 mg/dL (p<0.05). As like LDL-C, there was much reduction 
in VLDL-C due to extract administration in EDCN rats compared to 
glibenclamide administration in GDCN rats.
There was 8-10 mg/dL (p<0.001) more significant reduction of VLDL-C 
by extract in EDCN compared to one observed in GDCN group (Table 3).
Total serum cholesterol is an important parameter in prediction of 
cardiovascular complication of diabetes. Caffeine-nicotine exaggerates 
total serum cholesterol by at least 10-15 mg/dL over plane diabetic 
control. Extract treatment brake this rise by at least 60-80 mg/dL 
(p<0.01) in comparison to control groups. Extract reduce 10-15 mg/dL 
of more cholesterol than that of standard drug as depicted in Fig. 3.
DISCUSSION
This research protocol was continuation of our previous work Kumbhar 
et al. where we demonstrated exaggeration of Type 2 diabetes 
by caffeine nicotine coadministration in diabetic rats [7]. We also 
conducted another study where we proposed significant antidiabetic 
activity of CI extract in SD rats [15]. The purpose of this study was to 
treat caffeine-nicotine exaggerated diabetes in animals using existing 
standard drug as well as effective dose of CI extract orally in separate 
rat groups. This study used HFD/STZ model to induce Type 2 diabetes 
in SD rats. This study assumes that the caffeine and nicotine injected in 
animals induce an addiction as they do in human beings.
For diabetes induction, standard diet was mixed with the vegetable source 
ghee in such a concentration that ghee contributed 40% calories of the 
diet. All the groups were fed with this HFD for 2 weeks prior STZ injection. 
On 7th day, STZ (assay >98%) was diluted in cold citrate buffer and injected 
intraperitoneally in all rats. The induction of diabetes was confirmed by 
polyuria and polyphagia produced in animals. Initially, 10 rats were taken 
in each group and four unstable rats, in terms of glucose level and body 
weight; were removed from each group. After STZ injection, all rats were 
maintained on standard pellet diet and sufficient water in air conditioned 
room where temperature and moisture was maintained with at most 
care. Because these conditions generally alter hormonal secretions in the 
animal body and may interfere with the experiment results.
Caffeine (assay >98%) and nicotine (assay >95%) were measured 
carefully; diluted in saline and administered intraperitoneally twice 
daily in their normal doses to create addiction [9]. There was no 
Fig. 1: Body weight changes (n=6). D: Diabetic control group; 
DCN: Caffeine-nicotine diabetic group, EDCN: Extract-treated 
caffeine-nicotine diabetic group. GDCN: Gibenclamide-treated 
caffeine-nicotine diabetic group. Results expressed as 
mean±standard error of mean and compared with diabetic 
caffeine-nicotine control group; difference analyzed among 
groups using one-way ANOVA and Dunnett’s t post-test. aDifference 
between a treatment group and DCN control group significant at 
p<0.05, bdifference between a treatment group and DCN control 
group significant at p<0.01, xdifference among plane diabetic and 
caffeine-nicotine diabetic control groups significant at p<0.05
Fig. 2: Serum fasting glucose levels (n=6). D: Diabetic 
control group; DCN: Caffeine-nicotine diabetic group, 
EDCN: Extract-treated caffeine-nicotine diabetic group, 
GDCN: Glibenclamide-treated caffeine-nicotine diabetic 
group. Results expressed as mean±standard error of mean 
and compared with diabetic caffeine-nicotine control group; 
Difference analyzed among groups using one-way ANOVA 
and Dunnett’s t post-test. aDifference between two groups 
is significant at p<0.05, bdifference between two groups is 
significant at p<0.01, xdifference among plane diabetic and 
caffeine-nicotine diabetic control groups significant at p<0.05
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point in giving these drugs orally as this would have changed their 
bioavailability due to unpredictable absorption and presystemic 
metabolism. Their oral stability was another limitation particularly for 
volatile nicotine.
Based on the literature survey, this is the first study where we treated 
caffeine-nicotine-induced exaggeration of Type 2 diabetes using herbal 
drug and compared it with modern allopathic drug. Caffeine-nicotine 
addiction reduces the response of animals to the glibenclamide 
while extract suppress this effect of addiction. Hypoglycemic drugs 
control hyperglycemia but generally cannot control other diabetic 
complications in effective manner and herbal drugs do better in this 
situation. If we compare the results of kidney and liver function test; 
it is evident that extract controlled damage of these organs better than 
standard drug did. Triglyceridemia is one of the most observed diabetic 
complications in most patients [18]. Triglyceridemia leads to system 
acidosis and ketone body formation. These ketone bodies liberate free 
radicles which are capable of producing several damages to sensitive 
organs. Extract carrier lots antioxidant compounds which might be 
inhibiting this ketone body formation and related tissue toxicity [19].
Diabetes is known to produce cardiovascular complications. 
Hyperglycemia leads to hypervolumia and it further leads to 
hypertension. This hypertension, which fluctuates with blood 
glucose, is very harmful parameter. Cholesterol metabolism gets 
disturbed and it promotes atherosclerotic plug formation in delicate 
arteries. When this effect targets coronary artery it may lead to 
acute sever blockade of this very vital artery [20]. Extract treatment 
shifted this cholesterol dynamics form bad cholesterol to good 
cholesterol. Extract treatment reduced cholesterol form LDL, VLDL 
and TC and increased it into HDL [21]. This change clearly indicates 
the hypolipidemic potential of this herbal extract. This shift in 
cholesterol is an important step toward reducing unwanted body 
weight and controlling obesity [22].
Table 1: Liver function test (n=6)
Group ALT levels (U/L) AST levels (U/L)
Day 1 Day 7 Day 14 Day 21 Day 1 Day 7 Day 14 Day 21
D 42±2.7 81±5.6 86±3.1 92±3.3 123±9.4 280±16.4 301±17.4 311±19.4
DCN 41±3.0 99±3.4x 107±2.9x 113±3.4x 117±9.4 307±13.8 335±15.4 359±16.4x
EDCN 40±2.8 61±2.9a 54±2.9b 59±3.2b 119±8.6 211±14.3b 188±16.4b 171±18.7c
GDCN 39±2.7 68±2.9 72±3.0a 79±2.8a 129±4.5 235±15.4a 207±13.4a 178±17.9c
D: Diabetic control group; DCN: Diabetes and caffeine-nicotine both simultaneously; EDCN:Extract treated caffeine-nicotine diabetic group. GDCN: Glibenclamide treated 
caffeine-nicotine diabetic group. Results expressed as Mean ± SEM. Results were compared with diabetic caffeine-nicotine control group; Difference analyzed amongst 
groups using one-way ANOVA and Dunnett’s t post-test. aDifference amongst two groups is significant at p<0.05. bDifference amongst two groups is significant at 
p<0.01.x: Difference amongst plane diabetic and caffeine-nicotine diabetic control groups significant at p<0.05.
Table 2: Kidney function test (n=6)
Group Serum urea (mg/dL) Serum creatinine (mg/dL)
Day 1 Day 7 Day 14 Day 21 Day 1 Day 7 Day 14 Day 21
D 18±3.2 64±4.1 67±4.3 69±4.4 0.37±0.04 0.63±0.05 0.68±0.05 0.73±0.05
DCN 19±4.6 67±4.0 76±4.1 86±4.2x 0.36±0.04 0.73±0.04 0.89±0.05x 0.96±0.05x
EDCN 17±4.3 32±3.9b 33±4.1b 36±4.0c 0.38±0.04 0.54±0.05 0.49±0.04a 0.41±0.04b
GDCN 19±4.1 31±3.8b 28±4.9c 30±4.2c 0.31±0.04 0.65±0.05 0.74±0.05 0.71±0.05
D: Diabetic control group; DCN: Diabetes and caffeine-nicotine both simultaneously; EDCN:Extract treated caffeine-nicotine diabetic group. GDCN: Glibenclamide treated 
caffeine-nicotine diabetic group. Results expressed as Mean ± SEM. Results were compared with diabetic caffeine-nicotine control group; Difference analyzed amongst 
groups using one-way ANOVA and Dunnett’s t post-test. aDifference amongst two groups is significant at p<0.05. bDifference amongst two groups is significant at 
p<0.01.x: Difference amongst plane diabetic group and caffeine-nicotine diabetic control group significant at p<0.05.
Table 3: Serum lipid levels (n=6)
Group Serum triglycerides (mg/dL) Serum HDL-C (mg/dL)
Day 1 Day 7 Day 14 Day 21 Day 1 Day 7 Day 14 Day 21
D 51±7.2 80±7.8 83±8.2 88±9.1 53±3.5 51±4.1 48±4.4 44±4.6
DCN 47±7.3 81±7.3 98±7.8 103±7.2x 49±3.2 46±3.8 42±4.0 38±3.9x
EDCN 53±7.0 63±8.3a 59±7.7b 60±7.6b 48±3.4 52±3.9 57±3.6a 56±3.8b
GDCN 50±7.6 61±8.9a 63±8.7a 67±8.1a 51±3.4 53±3.7 58±3.4a 61±3.7b
Group Serum LDL-C (mg/dL) Serum VLDL-C (mg/dL)
Day 1 Day 7 Day 14 Day 21 Day 1 Day 7 Day 14 Day 21
D 65±6 112±09 119±11 122±9 19±1.3 29±1.5 31±1.4 33±1.6
DCN 58±9 113±10 128±8 139±8x 20±1.1 34±1.5 37±1.4x 40±1.6x
EDCN 67±7 89±10a 81±9b 072±9b 21±1.3 22±1.2a 21±1.1b 23±1.2c
GDCN 69±9 80±07 79±8b 83±11b 20±1.3 26±1.4 27±1.2 29±1.3a
D: Diabetic control group; DCN: Diabetes and caffeine-nicotine both simultaneously; EDCN:Extract treated caffeine-nicotine diabetic group. GDCN: Glibenclamide treated 
caffeine-nicotine diabetic group. Results expressed as Mean ± SEM. Results were compared with diabetic caffeine-nicotine control group; Difference analyzed amongst 
groups using one-way ANOVA and Dunnett’s t post-test. aDifference amongst two groups is significant at p<0.05. bDifference amongst two groups is significant at 
p<0.01.x: Difference amongst plane diabetic group and caffeine-nicotine diabetic control group significant at p<0.05.
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CONCLUSION
We conclude that like standard drug glibenclamide, CI extract can 
be used to treat caffeine-nicotine-induced exaggeration of Type 2 
diabetes. Although it is herbal drug, CI extract has better potency and 
very useful activity profile in controlling blood glucose, proteins, and 
fats (cholesterol) metabolism. It also resists diabetes-induced weight 
loss and muscular weakness. CI treatment protects kidney and liver 
like vital organs which are slowly but progressively damaged by Type 2 
diabetes. Hence, we propose that CI herbal extract is better drug in 
controlling diabetes Type 2 in addicted patients. This finding is based 
on animal, i.e., rat experiment; and it must be tested further in human 
beings by conducting appropriate clinical trial.
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Fig. 3: Serum total cholesterol (n=6). D: Diabetic control group, 
DCN: Diabetes and caffeine-nicotine both simultaneously, 
EDCN: Extract-treated caffeine-nicotine diabetic group, 
GDCN: Glibenclamide-treated caffeine-nicotine diabetic group. 
Results expressed as mean±standard error of mean. Results 
were compared with diabetic caffeine-nicotine control group; 
Difference analyzed among groups using one-way ANOVA 
and Dunnett’s t post-test. aDifference between two groups 
is significant at p<0.05, bdifference between two groups is 
significant at p<0.01, xdifference among plane diabetic group and 
caffeine-nicotine diabetic control group significant at p<0.05
